The Lithium Neutron Capture Therapy (Li-NCT) market in Latin America is in its formative stages, with growing interest from public health institutions and academic research centers. The key market driver is the region's increasing cancer incidence, particularly in hard-to-treat tumors like glioblastoma and pancreatic cancer, where conventional therapies offer limited survival benefit. Government-backed health initiatives are encouraging innovative oncology treatments, but the region still faces a significant restraint in the form of limited infrastructure for neutron generation and the high capital investment required. Moreover, regulatory uncertainty around nuclear-based therapies poses an additional challenge. However, the region offers notable opportunities through international research collaborations, particularly with countries in Europe and Asia investing in global clinical trials. Trends such as the integration of nuclear medicine into national cancer plans and the rise of PPPs (Public-Private Partnerships) in Brazil, Mexico, and Argentina are reshaping the therapeutic landscape. As such, the LATAM Li-NCT market is anticipated to expand at a CAGR of approximately 9.2% between 2025 and 2032, with significant momentum expected after 2028 as pilot treatment centers begin operations and technology transfer accelerates.
TABLE - LATAM LATAM Lithium Neutron Capture Therapy Market Size & Forecast 2021 – 2033
LATAM | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Brazil | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Mexico | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Argentina | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Chile | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Colombia | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Rest of LATAM | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - LATAM Lithium Neutron Capture Therapy Market Size & Forecast By Therapy Type 2021-2033
Therapy Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Monotherapy | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Combination Therapy | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - LATAM Lithium Neutron Capture Therapy Market Size & Forecast By Application 2021-2033
Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Brain Tumors | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Head and Neck Cancers | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Others | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - LATAM Lithium Neutron Capture Therapy Market Size & Forecast By End-User 2021-2033
End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospitals with Advanced Radiotherapy Units | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Research Institutes | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Specialty Cancer Centers | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis